Gender analysis of moxifloxacin clinical trials
Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10045/33739
Título: | Gender analysis of moxifloxacin clinical trials |
---|---|
Autor/es: | Chilet Rosell, Elisa | Ruiz-Cantero, María Teresa | Pardo López, María Ángeles |
Grupo/s de investigación o GITE: | Salud Pública |
Centro, Departamento o Servicio: | Universidad de Alicante. Departamento de Enfermería Comunitaria, Medicina Preventiva y Salud Pública e Historia de la Ciencia |
Palabras clave: | Gender | Women | Health | Moxifloxacin | Clinical trials |
Área/s de conocimiento: | Medicina Preventiva y Salud Pública |
Fecha de publicación: | 1-nov-2013 |
Editor: | Mary Ann Liebert |
Cita bibliográfica: | Elisa Chilet-Rosell, Ma Teresa Ruiz-Cantero, and Ma Angeles Pardo. Journal of Women's Health. Online Ahead of Print: November 1, 2013. doi:10.1089/jwh.2012.4171 |
Resumen: | Purpose: To determine the inclusion of women and the sex-stratification of results in moxifloxacin Clinical Trials (CTs), and to establish whether these CTs considered issues that specifically affect women, such as pregnancy and use of hormonal therapies. Previous publications about women’s inclusion in CTs have not specifically studied therapeutic drugs. Although this type of drug is taken by men and women at a similar rate, adverse effects occur more frequently in the latter. Methods: We reviewed 158 published moxifloxacin trials on humans, retrieved from MedLine and the Cochrane Library (1998–2010), to determine whether they complied with the gender recommendations published by U.S. Food and Drug Administration Guideline. Results: Of a total of 80,417 subjects included in the moxifloxacin CTs, only 33.7% were women in phase I, in contrast to phase II, where women accounted for 45%, phase III, where they represented 38.3% and phase IV, where 51.3% were women. About 40.9% (n = 52) of trials were stratified by sex and 15.3% (n = 13) and 9% (n = 7) provided data by sex on efficacy and adverse effects, respectively. We found little information about the influence of issues that specifically affect women. Only 3 of the 59 journals that published the moxifloxacin CTs stated that authors should stratify their results by sex. Conclusions: Women are under-represented in the published moxifloxacin trials, and this trend is more marked in phase I, as they comprise a higher proportion in the other phases. Data by sex on efficacy and adverse effects are scarce in moxifloxacin trials. These facts, together with the lack of data on women-specific issues, suggest that the therapeutic drug moxifloxacin is only a partially evidence-based medicine. |
URI: | http://hdl.handle.net/10045/33739 |
ISSN: | 1540-9996 (Print) | 1931-843X (Online) |
DOI: | 10.1089/jwh.2012.4171 |
Idioma: | eng |
Tipo: | info:eu-repo/semantics/article |
Derechos: | This is a copy of an article published in the Journal of Women's Health © 2013 Mary Ann Liebert, Inc.; Journal of Women's Health is available online at: http://online.liebertpub.com. |
Revisión científica: | si |
Versión del editor: | http://dx.doi.org/10.1089/jwh.2012.4171 |
Aparece en las colecciones: | INV - SP - Artículos de Revistas Institucional - IUIEG - Publicaciones |
Archivos en este ítem:
Archivo | Descripción | Tamaño | Formato | |
---|---|---|---|---|
2013_Chilet_etal_JWH.pdf | 461,07 kB | Adobe PDF | Abrir Vista previa | |
Todos los documentos en RUA están protegidos por derechos de autor. Algunos derechos reservados.